Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STORM trial of temsirolimus added to rituximab + DHAP in relapsed or refractory diffuse large B-cell lymphoma
2011-001491-20Phase 2Completed
- Sponsor
- Heidelberg University
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of temsirolimus in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Heidelberg University. Primary endpoint: Maximum tolerated dose of temsirolimus in combination with rituximab and DHAP. Started Jul 2012; status: completed.
02
Drugs
temsirolimus
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2011-001491-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001491-20.